SymBio Pharmaceuticals (TSE:4582) Retained Earnings: 円-37,462 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
36 GF Score
Price 円69.00
GF Value 円59.93
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Retained Earnings?

SymBio Pharmaceuticals TSE:4582 36 Retained Earnings is 円-37,462 Mil as of Dec. 2025. GuruFocus rates TSE:4582 with a GF Score™ of 36/100 and a GF Value™ of 円59.93 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. SymBio Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2025 was 円-37,462 Mil.

SymBio Pharmaceuticals's quarterly retained earnings declined from Jun. 2025 (円-35,055 Mil) to Sep. 2025 (円-36,251 Mil) and declined from Sep. 2025 (円-36,251 Mil) to Dec. 2025 (円-37,462 Mil).

SymBio Pharmaceuticals's annual retained earnings declined from Dec. 2023 (円-28,852 Mil) to Dec. 2024 (円-32,686 Mil) and declined from Dec. 2024 (円-32,686 Mil) to Dec. 2025 (円-37,462 Mil).


SymBio Pharmaceuticals  (TSE:4582) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


SymBio Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Retained Earnings Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27,977.51 -26,889.49 -28,852.30 -32,685.78 -37,461.98

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34,006.78 -35,054.97 -36,251.44 -37,461.98 -39,863.38
TSE:4582
36GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of 円-37,462 Mil mean?
SymBio Pharmaceuticals (TSE:4582) has a Retained Earnings of 円-37,462 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Retained Earnings too high?
SymBio Pharmaceuticals' current Retained Earnings is 円-37,462 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Retained Earnings compare to ZTS?
SymBio Pharmaceuticals' Retained Earnings of 円-37,462 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Retained Earnings is 円-37,462 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Modestly Overvalued. The stock's GF Value™ is 円59.93, compared to a current price of 円69.00 — trading 15.1% above its estimated fair value. The current Retained Earnings is 円-37,462 Mil. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Retained Earnings is 円-37,462 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円69.00 is trading 15.1% above its estimated GF Value™ of 円59.93. GuruFocus considers SymBio Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for TSE:4582:

  • Retained Earnings: 円-37,462 Mil
  • GF Value™: 円59.93 vs. price of 円69.00 (15.1% above fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for TSE:4582

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円69.00
Price
円59.93
GF Value